Table 5.
Relationship between (MV + FA)/BMI supplementation dose and HDCP.
| (MV + FA)/BMI | First trimester | Whole pregnancy | ||||||
|---|---|---|---|---|---|---|---|---|
| Case | Controls | RR | 95% CI | Case | Controls | RR | 95% CI | |
| Q1 (4.26-8.33) | 7 | 803 | 1 | 2 | 273 | 1 | ||
| Q2 (8.34-13.33) | 12 | 730 | 0.6 | 0.31-1.15 | 6 | 316 | 1.09 | 0.42-2.87 |
| Q3 (13.34-15.38) | 16 | 848 | 0.52 | 0.26-1.07 | 9 | 375 | 0.79 | 0.28-2.25 |
| Q4 (15.39-21.05) | 22 | 702 | 0.28 | 0.12-0.65 | 8 | 305 | 0.31 | 0.06-1.42 |
| Total | 57 | 3083 | 25 | 1269 | ||||
| P Trend | 0.00 | 0.13 | ||||||
∗ : adjusted for education, prepregnancy BMI, age, weight gain during pregnancy, ethnicity, infant gender, and primiparity. (MV + FA)/BMI: (MVs + FA)/BMI, HDCP: hypertensive disorder complicating pregnancy; case: HDCP, controls: non-HDCP.